Capillary Biomedical said today that it raised $2.9 million in a seed funding round to support regulatory filings and the launch of its insulin infusion technology.
The company is gearing up for clinical trials to support a 510(k) filing and hopes to bring its SteadiSet infusion set to the market in 2019.
Get the full story at our sister site, Drug Delivery Business News.
The post Capillary Biomedical raises $3m to support insulin infusion tech appeared first on MassDevice.
from MassDevice https://ift.tt/2Mlc8vR
Cap comentari:
Publica un comentari a l'entrada